
Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to ...
FOSTER CITY, Calif., May 30, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, is presenting …